SI2403528T1 - Protitelesa proti proliferacijo inducirajočemu ligandu (april) - Google Patents
Protitelesa proti proliferacijo inducirajočemu ligandu (april)Info
- Publication number
- SI2403528T1 SI2403528T1 SI201031186A SI201031186A SI2403528T1 SI 2403528 T1 SI2403528 T1 SI 2403528T1 SI 201031186 A SI201031186 A SI 201031186A SI 201031186 A SI201031186 A SI 201031186A SI 2403528 T1 SI2403528 T1 SI 2403528T1
- Authority
- SI
- Slovenia
- Prior art keywords
- april
- antibodies against
- inducing ligand
- proliferating
- proliferating inducing
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09154079 | 2009-03-02 | ||
| EP09157722 | 2009-04-09 | ||
| PCT/EP2010/052254 WO2010100056A2 (en) | 2009-03-02 | 2010-02-23 | Antibodies against a proliferating inducing ligand (april) |
| EP10706979.1A EP2403528B1 (en) | 2009-03-02 | 2010-02-23 | Antibodies against a proliferating inducing ligand (april) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI2403528T1 true SI2403528T1 (sl) | 2016-07-29 |
Family
ID=42289631
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201031186A SI2403528T1 (sl) | 2009-03-02 | 2010-02-23 | Protitelesa proti proliferacijo inducirajočemu ligandu (april) |
Country Status (16)
| Country | Link |
|---|---|
| US (4) | US8895705B2 (sl) |
| EP (3) | EP2403528B1 (sl) |
| JP (3) | JP5867706B2 (sl) |
| AR (1) | AR075604A1 (sl) |
| AU (1) | AU2010220421B9 (sl) |
| CA (2) | CA2754127C (sl) |
| CY (1) | CY1117942T1 (sl) |
| DK (2) | DK3103476T3 (sl) |
| ES (2) | ES2928709T3 (sl) |
| HR (1) | HRP20160702T1 (sl) |
| HU (1) | HUE027826T2 (sl) |
| PL (1) | PL2403528T3 (sl) |
| PT (1) | PT2403528E (sl) |
| SI (1) | SI2403528T1 (sl) |
| SM (1) | SMT201600239B (sl) |
| WO (1) | WO2010100056A2 (sl) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2754127C (en) | 2009-03-02 | 2017-04-18 | Stichting Top Institute Pharma | Antibodies against a proliferating inducing ligand (april) |
| WO2013183786A1 (ja) * | 2012-06-08 | 2013-12-12 | 学校法人近畿大学 | トランスポーターに対する抗体およびその用途 |
| NL2011406C2 (en) * | 2013-09-06 | 2015-03-10 | Bionovion Holding B V | Method for obtaining april-binding peptides, process for producing the peptides, april-binding peptides obtainable with said method/process and use of the april-binding peptides. |
| US20160356794A1 (en) * | 2014-02-10 | 2016-12-08 | Merck Sharp & Dohme Corp. | Antibodies that bind to human tau and assay for quantifying human tau using the antibodies |
| EP3107582A4 (en) * | 2014-02-19 | 2018-02-14 | Emergent BioSolutions Canada Inc. | Ebola monoclonal antibodies |
| CA2939293C (en) | 2014-03-11 | 2023-10-03 | The Board Of Trustees Of The Leland Standford Junior University | Anti sirp-alpha antibodies and bi-specific macrophage enhancing antibodies |
| NL2014108B1 (en) | 2015-01-09 | 2016-09-30 | Aduro Biotech Holdings Europe B V | Altered april binding antibodies. |
| WO2016113368A1 (en) | 2015-01-15 | 2016-07-21 | Universite Grenoble Alpes | Anti april (a proliferation-inducing ligand) antibodies and their uses for the prognosis and/or diagnosis of cancer |
| MY190404A (en) | 2015-03-10 | 2022-04-21 | Aduro Biotech Inc | Compositions and methods for activating "stimulator of interferon gene"-dependent signalling |
| MX2018006385A (es) * | 2015-11-25 | 2019-09-11 | Visterra Inc | Moleculas de anticuerpo contra april y usos de las mismas. |
| EP3389630B1 (en) | 2015-12-16 | 2023-11-08 | Gritstone bio, Inc. | Neoantigen identification, manufacture, and use |
| WO2018009466A1 (en) | 2016-07-05 | 2018-01-11 | Aduro Biotech, Inc. | Locked nucleic acid cyclic dinucleotide compounds and uses thereof |
| JP7128829B2 (ja) | 2017-02-17 | 2022-08-31 | マップ バイオファーマシューティカル、インコーポレイテッド | エボラ感染症の処置用のモノクローナル抗体およびカクテル |
| UY37695A (es) | 2017-04-28 | 2018-11-30 | Novartis Ag | Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo |
| SG11202001847WA (en) | 2017-08-30 | 2020-03-30 | Beijing Xuanyi Pharmasciences Co Ltd | Cyclic di-nucleotides as stimulator of interferon genes modulators |
| CA3078744A1 (en) | 2017-10-10 | 2019-04-18 | Gritstone Oncology, Inc. | Neoantigen identification using hotspots |
| KR20200090855A (ko) | 2017-11-22 | 2020-07-29 | 그릿스톤 온콜로지, 인코포레이티드 | 신생항원에 대한 접합 에피토프 제시 감소 |
| WO2020144535A1 (en) | 2019-01-08 | 2020-07-16 | Aduro Biotech Holdings, Europe B.V. | Methods and compositions for treatment of multiple myeloma |
| KR20230017223A (ko) * | 2020-05-29 | 2023-02-03 | 치누크 세라퓨틱스, 인크. | APRIL 결합 항체로 IgA 신장병증을 치료하는 방법 |
| WO2023212518A1 (en) | 2022-04-25 | 2023-11-02 | Visterra, Inc. | Antibody molecules to april and uses thereof |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US778A (en) | 1838-06-12 | Thomas wright | ||
| US4946A (en) | 1847-01-26 | Improvement in carriage-wheels | ||
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| EP0281604B1 (en) | 1986-09-02 | 1993-03-31 | Enzon Labs Inc. | Single polypeptide chain binding molecules |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| DE69233528T2 (de) | 1991-11-25 | 2006-03-16 | Enzon, Inc. | Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen |
| DE69434988T2 (de) | 1994-11-07 | 2008-03-06 | Human Genome Sciences, Inc. | Tumornekrose-faktor-gamma |
| US6171787B1 (en) | 1997-06-26 | 2001-01-09 | Abbott Laboratories | Member of the TNF family useful for treatment and diagnosis of disease |
| NZ503850A (en) | 1997-09-12 | 2002-12-20 | Apotech S | April - a novel protein with growth effects |
| ATE511857T1 (de) * | 2000-02-16 | 2011-06-15 | Genentech Inc | Anti-april monoklonaler antikörper und deren verwendung zur behandlung von immunerkrankungen oder krebs |
| MXPA02011130A (es) * | 2000-05-12 | 2003-03-10 | Amgen Inc | Metodos y composiciones de materia que se refieren a april/g70, bcma, blys/agp-3, y taci. |
| CA2413160A1 (en) | 2000-06-15 | 2001-12-20 | Human Genome Sciences, Inc. | Human tumor necrosis factor delta and epsilon |
| WO2002094192A2 (en) | 2001-05-24 | 2002-11-28 | Human Genome Sciences, Inc. | Antibodies against tumor necrosis factor delta (april) |
| US20050070689A1 (en) * | 2001-08-03 | 2005-03-31 | Genentech, Inc. | Taci and br3 polypeptides and uses thereof |
| WO2003086310A2 (en) | 2002-04-12 | 2003-10-23 | Ramot At Tel Aviv University Ltd. | Prevention of brain inflammation as a result of induced autoimmune response |
| US7410483B2 (en) | 2003-05-23 | 2008-08-12 | Novare Surgical Systems, Inc. | Hand-actuated device for remote manipulation of a grasping tool |
| US20070249530A1 (en) * | 2004-01-29 | 2007-10-25 | Genentech, Inc. | Bcma Polypeptides and Uses Thereof |
| DE602005022871D1 (de) | 2004-06-07 | 2010-09-23 | Univ Ramot | Verfahren zur passiven immunisierung gegen eine durch amyloidaggregation gekennzeichnete krankheit oder erkrankung mit vermindertem nervenentzündungsrisiko |
| EP1766083B1 (en) | 2004-07-15 | 2011-05-04 | Technische Universität Wien | Method for the detection of fusarium graminearum |
| CA2754127C (en) | 2009-03-02 | 2017-04-18 | Stichting Top Institute Pharma | Antibodies against a proliferating inducing ligand (april) |
-
2010
- 2010-02-23 CA CA2754127A patent/CA2754127C/en active Active
- 2010-02-23 EP EP10706979.1A patent/EP2403528B1/en active Active
- 2010-02-23 SI SI201031186A patent/SI2403528T1/sl unknown
- 2010-02-23 HU HUE10706979A patent/HUE027826T2/en unknown
- 2010-02-23 ES ES16075009T patent/ES2928709T3/es active Active
- 2010-02-23 ES ES10706979.1T patent/ES2573404T3/es active Active
- 2010-02-23 EP EP22186935.7A patent/EP4147719A1/en active Pending
- 2010-02-23 EP EP16075009.7A patent/EP3103476B1/en active Active
- 2010-02-23 PL PL10706979T patent/PL2403528T3/pl unknown
- 2010-02-23 AU AU2010220421A patent/AU2010220421B9/en active Active
- 2010-02-23 PT PT107069791T patent/PT2403528E/pt unknown
- 2010-02-23 JP JP2011552389A patent/JP5867706B2/ja active Active
- 2010-02-23 WO PCT/EP2010/052254 patent/WO2010100056A2/en active Application Filing
- 2010-02-23 CA CA2919467A patent/CA2919467C/en active Active
- 2010-02-23 DK DK16075009.7T patent/DK3103476T3/da active
- 2010-02-23 DK DK10706979.1T patent/DK2403528T3/en active
- 2010-02-25 AR ARP100100546A patent/AR075604A1/es not_active Application Discontinuation
-
2011
- 2011-08-24 US US13/216,751 patent/US8895705B2/en active Active
-
2013
- 2013-03-11 US US13/792,339 patent/US9000128B2/en active Active
- 2013-03-11 US US13/792,380 patent/US20130295103A1/en not_active Abandoned
- 2013-03-11 US US13/792,406 patent/US20130302353A1/en not_active Abandoned
-
2015
- 2015-06-10 JP JP2015117303A patent/JP2015172073A/ja not_active Withdrawn
- 2015-06-10 JP JP2015117304A patent/JP2015164956A/ja active Pending
-
2016
- 2016-05-20 HR HRP20160702TT patent/HRP20160702T1/hr unknown
- 2016-07-15 CY CY20161100688T patent/CY1117942T1/el unknown
- 2016-07-20 SM SM201600239T patent/SMT201600239B/it unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI2403528T1 (sl) | Protitelesa proti proliferacijo inducirajočemu ligandu (april) | |
| IL214996A0 (en) | Anti-bcma antibodies | |
| GB0920127D0 (en) | Antibodies | |
| GB0909906D0 (en) | Antibodies | |
| ZA201104545B (en) | Anti-siglec-15 antibody | |
| EP2427496A4 (en) | ANTI-VEGF-D ANTIBODIES | |
| ZA201209004B (en) | Anti-fgfr2 antibodies | |
| GB201000467D0 (en) | Antibodies | |
| IL221371A0 (en) | Anti-lrp6 antibodies | |
| GB0821100D0 (en) | Antibodies | |
| EP2337798A4 (en) | BSA-SPECIFIC ANTIBODIES | |
| HK1194388A1 (zh) | 抗缺刻蛋白 抗體 | |
| PT2603528T (pt) | Anticorpos glicosilados em fab | |
| GB201020738D0 (en) | Antibodies | |
| GB0920324D0 (en) | Antibodies | |
| GB201002238D0 (en) | Antibodies | |
| IL207581A0 (en) | Anti-tyrp1 antibodies | |
| HK1170745A1 (en) | Antibodies against il-17br il-17br | |
| ZA201302459B (en) | Antibodies | |
| ZA201203540B (en) | Tricyclic antibodies | |
| GB0818356D0 (en) | Antibodies | |
| GB2473934B (en) | Anti-VEEV antibody | |
| EP2499256A4 (en) | ANTI-C-MPL ANTIBODIES | |
| EP2511371A4 (en) | PEPTIDANT BODY AGAINST CANCER AND MORTALINE | |
| EP2424892A4 (en) | DC-STAMP ANTIBODY |